Key result
Platelet-inhibiting agents are of vital importance in preventing and treating cardiovascular diseases, including myocardial infarction, unstable angina, and stroke.
Platelet-inhibiting agents play a vital role in preventing and treating cardiovascular diseases such as myocardial infarction, unstable angina, and stroke, as well as serving as adjuvants following revascularization.
Affirms antiplatelet centrality in MI, angina, and stroke care; leaves open optimization questions for contemporary regimens.
Platelets contribute to normal hemostasis by adhering to subendothelial tissues after vascular damage has taken place and then recruiting additional platelets through the process of aggregation. Activation of the coagulation cascade ultimately results in fibrin deposition. In pathological conditions, thrombogenic surfaces act as a nidus for platelet adherence and thrombus formation. The ability of platelet-inhibiting agents to prevent or impair platelet-mediated thrombotic and thromboembolic events is of vital importance in the prevention and treatment of cardiovascular diseases, including myocardial infarction, unstable angina and stroke. They also serve as important adjuvants following percutaneous transluminal coronary angioplasty and saphenous vein bypass grafting. Future investigations will likely uncover additional indications.
No takes yet. Share an insight, caveat, or question.
R C Becker (2008) conducted a review in Cardiovascular diseases. Platelet-inhibiting agents was evaluated. Platelet-inhibiting agents are of vital importance in preventing and treating cardiovascular diseases, including myocardial infarction, unstable angina, and stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: